Drug Profile
Selatinib
Alternative Names: Selatinib ditosilateLatest Information Update: 10 May 2016
Price :
$50
*
At a glance
- Originator Qilu Pharmaceutical
- Class Antineoplastics; Quinazolines
- Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer